Factors for successful implementation of population-based expanded carrier screening: Learning from existing initiatives

European Journal of Public Health

Volumn 27, Issue 2, 2017, Pages 372-377

  Holtkamp, Kim C A ^a   Mathijssen, Inge B ^b   Lakeman, Phillis ^b   Van Maarle, Merel C ^b   Dondorp, Wybo J ^c   Henneman, Lidewij ^a   Cornel, Martina C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; FEMALE; GENETIC SCREENING; GENETICS; HETEROZYGOTE; HUMAN; JEW; MALE; MASS SCREENING; NETHERLANDS; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; GENETIC TESTING; HETEROZYGOTE; HUMANS; JEWS; MALE; MASS SCREENING; NETHERLANDS; YOUNG ADULT;

EID: 85017228098     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckw110     Document Type: Conference Paper

References (40)

1. Ropers HH. On the future of genetic risk assessment. J Community Genet 2012;3:229-36.
2. Kaback MM. Screening and prevention in Tay-Sachs disease: origins, update, and impact. Adv Genet 2001;44:253-65.
3. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet 2010;18:1077-83.
4. American College of Obstetricians and Gynecologists. Committee opinion no. 486. Update on carrier screening for cystic fibrosis. Obstet Gynecol 2011;117:1028-31.
5. Henneman L, Bramsen I, van der Ploeg HM, et al. Participation in preconceptional carrier couple screening: characteristics, attitudes, and knowledge of both partners. J Med Genet 2001;38:695-703.
6. Lakeman P, Plass AM, Henneman L, et al. Preconceptional ancestry-based carrier couple screening for cystic fibrosis and haemoglobinopathies: what determines the intention to participate or not and actual participation? Eur J Hum Genet 2009;17:999-1009.
7. Ioannou L, McClaren BJ, Massie J, et al. Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research. Genet Med 2014;16: 207-16.
8. Janssens S, De Paepe A, Borry P. Attitudes of health care professionals toward carrier screening for cystic fibrosis. A review of the literature. J Community Genet 2014;5:13-29.
9. Edwards JG, Feldman G, Goldberg J, et al. Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American college of medical genetics and genomics, American college of obstetricians and gynecologists, national society of genetic counselors, perinatal quality foundation, and society for maternal-fetal medicine. Obstet Gynecol 2015;125:653-62.
10. Henneman L, Borry P, Chokoshvilli D, et al. Responsible implementation of expanded carrier screening. Eur J Hum Genet 2016;24:e1-e12.
11. De Wert G, Dondorp W, Knoppers B. Preconception care and genetic risk: ethical issues. J Community Genet 2012;3:221-8.
12. Grol R, Wensing M. What drives change? Barriers to and incentives for achieving evidence-based practice. Med J Aust 2004;180 Suppl 6:S57-60.
13. Achterbergh R, Lakeman P, Stemerding D, et al. Implementation of preconceptional carrier screening for cystic fibrosis and haemoglobinopathies: a sociotechnical analysis. Health Policy 2007;83:277-86.
14. Mathijssen IB, Henneman L, van Eeten-Nijman JM, et al. Targeted carrier screening for four recessive disorders: high detection rate within a founder population. Eur J Med Genet 2015;58:123-8.
15. Gross SJ, Pletcher BA, Monaghan KG. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 2008;10:54-6.
16. Ioannou L, Massie J, Lewis S, et al. Evaluation of a multi-disease carrier screening programme in Ashkenazi Jewish high schools. Clin Genet 2010;78:21-31.
17. Raz AE, Vizner Y. Carrier matching and collective socialization in community genetics: Dor Yeshorim and the reinforcement of stigma. Soc Sci Med 2008;67: 1361-9.
18. Holtkamp KCA, van Maarle MC, Schouten MJE, et al. People from the Jewish community prefer ancestry-based or pan-ethnic expanded carrier screening. Eur J Hum Genet 2016;24:171-7.
19. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci 2009;4:50.
20. Etchegary H, Potter B, Howley H, et al. The influence of experiential knowledge on prental screening and testing decisions. Genet Test 2008;12:115-24.
21. Archibald AD, McClaren BJ. Perceived relevance of genetic carrier screening: observations of the role of health-related life experiences and stage of life in decision making. J Community Genet 2012;3:47-54.
22. Archibald AD, Jaques AM, Wake S, et al. "It's something I need to consider": decisions about carrier screening for fragile X syndrome in a population of nonpregnant women. Am J Med Genet 2009;149:2731-8.
23. Hegwer G, Fairley C, Charrow J, Ormond KE. Knowledge and attitudes toward a free education and Ashkenazi Jewish carrier testing program. J Genet Counsel 2006;15:61-70.
24. Chen LS, Goodson P. Factors affecting decisions to accept or decline cystic fibrosis carrier testing/screening: a theory-guided systematic review. Genet Med 2007;9:442-50.
25. Laberge AM, Watts C, Porter K, Burke W. Assessing the potential success of cystic fibrosis carrier screening: lessons learned from Tay-Sachs disease and beta-thalassemia. Public Health Genomics 2010;13:310-9.
26. Consedine NS, Magai C, Krivoshekova YS, et al. Worry, and breast cancer screening behavior: a critical review. Cancer Epidemiol Biomarkers Prev 2004;13:501-10.
27. De Jonge ETM, Vlasselaer J, Van de Putte G, Schobbens JC. The construct of breast cancer risk perception: need for a better risk communication? Facts Views Vis Obgyn 2009;1:122-9.
28. Glanz K, Rimer BK, Viswanath K. Health Behavior and Health Education: Theory, Research, and Practice, 4th edn.. San Francisco, CA: Jossey-Bass, 2008.
29. Becker MH, Kaback MM, Rosenstock IM, Ruth MV. Some influences on public participation in a genetic screening program. J Community Health 1975;1:3-14.
30. Van der Pal SM, van Kesteren NM, van Wouwe JP, et al. The attitudes and intention to participate in hemoglobinopathy carrier screening in The Netherlands among individuals from Turkish, Moroccan, and Surinamese descent. J Environ Public Health 2013;2013:374831.
31. Poppelaars FA, Henneman L, Ader HJ, et al. Preconceptional cystic fibrosis carrier screening: attitudes and intentions of the target population. Genet Test 2004;8:80-9.
32. U.S. Congress OoTA. Cystic Fibrosis and DNA Tests: Implications of Carrier Screening. Washington, DC: U.S. Government Printing Office, 1992.
33. Ferreira JC, Schreiber-Agus N, Carter SM, et al. Carrier testing for Ashkenazi Jewish disorders in the prenatal setting: navigating the genetic maze. Am J Obstet Gynecol 2014;211:197-204.
34. Henneman L, Timmermans DRM, van der Wal G. Public experiences, knowledge and expectations about medical genetics and the use of genetic information. Community Genet 2004;7:33-43.
35. Schneider J, Goddard K, Davis J, et al. "Is it worth knowing?" Focus group participants' perceived utility of genomic preconception carrier screening. J Genet Counsel 2016;25:135-145.
36. McClaren BJ, Delatycki MB, Collins V, et al. "It is not in my world": an exploration of attitudes and influences associated with cystic fibrosis carrier screening. Eur J Hum Genet 2008;16:435-44.
37. Broens THF, Huis in't Veld MHA, Vollenbroek-Hutten MMR, et al. Determinants of successful telemedicine implementations: a literature study. J Telemed Telecare 2007;13:303-9.
38. Darr A, Small N, Ahmad WIU, et al. Examining the family-centred approach to genetic testing and counselling among UK Pakistanis: a community perspective. J Community Genet 2013;4:49-57.
39. Ekstein J, Katzenstein H. The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Adv Genet 2001;44:297-310.
40. Dondorp W, de WG, Bombard Y, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet 2015;23:1438-50.